Teicoplanin in the treatment of gram-positive-bacterial endocarditis.

AUTOR(ES)

Martino, P

RESUMO

Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usually with 3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h. For some cases (staphylococcal and enterococcal endocarditis), the dosage was 8 to 14.4 mg/kg per day and/or other antibiotics were given. The mean duration was 48.2 days (range, 23 to 130 days). Of 23 patients, 21 (91.3%) had negative cultures or were cured. A total of 18 patients were treated with teicoplanin alone; of these, 4 had surgery, and all (except 2 who relapsed) were cured. Teicoplanin was combined with one or more antibiotics in five cases; in all cases appropriate cultures were negative, but three patients died during therapy or follow-up. Mild renal impairment was seen in two patients; both were receiving teicoplanin in combination with an aminoglycoside. We conclude that intravenous teicoplanin administered once a day at doses of 7 to 14 mg/kg per day is well tolerated, easy to administer, and may represent an efficacious therapy for gram-positive-bacterial endocarditis.

Documentos Relacionados

• Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.
• Virulence factors among gram-positive bacteria in experimental endocarditis.
• Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis.
• Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
• Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.